Zealand Pharma Advances Petrelintide into Phase 3 as Amylin Analog Obesity Pipeline Expands

Zealand Pharma's decision to advance petrelintide into Phase 3 registrational trials in H2 2026 signals an imminent scale-up challenge for CDMOs and manufacturing operations teams working in the obesity therapeutics space. The amylin analog posted double-digit weight reduction in the Phase 2 ZUPREME-1 trial, with a tolerability profile described as largely comparable to placebo, a profile that, if sustained, positions petrelintide as a differentiated candidate in a crowded GLP-1-dominated market.

For plant heads and QA directors, the transition from Phase 2 to Phase 3 manufacturing for a peptide-based amylin analog carries distinct formulation and process validation demands. Amylin analogs present known aggregation and stability challenges that require tightly controlled sterile fill-finish environments and robust sterility assurance programs aligned with 21 CFR Part 211 and ICH Q10 quality system expectations. The scale of a registrational program, with multiple global sites likely required, compresses the timeline for process characterisation and comparability studies.

Survodutide, Zealand's glucagon/GLP-1 receptor dual agonist partnered with Boehringer Ingelheim, added further pipeline weight during the period. The SYNCHRONIZE-1 Phase 3 trial met its primary endpoints, recording up to 16.6% weight loss, with lean mass loss representing no more than 11.3% of total tissue mass change at the highest dose. Remaining Phase 3 obesity readouts for survodutide are expected later in 2026, sustaining regulatory and manufacturing planning pressure across the programme.

On the financial side, Zealand reported H1 2026 revenue of DKK 4,525 million, down from DKK 9,096 million in H1 2025, with operating profit of DKK 3,321 million against DKK 7,931 million in the prior period. A cash position of DKK 14,457 million as of June 30, 2026, was supported by a USD 200 million share buyback and a USD 100 million royalty monetisation agreement with Royalty Pharma covering rusfertide. The company also initiated a Phase 1b trial for ZP9830, a novel Kv1.3 ion channel blocker, in psoriasis patients, extending its pipeline into autoimmune and inflammatory indications.

The Phase 3 initiation timeline for petrelintide, planned for later in 2026, sets a near-term checkpoint for manufacturing readiness, with process validation packages and clinical supply agreements likely requiring finalisation before year-end.

Source: Zealand Pharma A/S via GlobeNewswire, August 13, 2026.